Clinical Trials Logo

Clinical Trial Summary

This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB2916 injection in patients with advanced tumors, and to initially evaluate the antitumor efficacy of TQB2916 injection.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05213767
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Yi Ba, Doctor
Phone 18622221230
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date February 2022
Completion date July 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05429008 - A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm Phase 1
Recruiting NCT05390528 - A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma Phase 1/Phase 2
Completed NCT02419417 - Study of BMS-986158 in Subjects With Select Advanced Cancers Phase 1/Phase 2
Recruiting NCT04808453 - Phase I Study of CPI-300 in Patients With Advanced Tumors Phase 1
Recruiting NCT04198818 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Phase 1/Phase 2
Not yet recruiting NCT04151810 - Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05068856 - A Study of HRS2543 in Patients With Advanced Tumors Phase 1
Completed NCT03781362 - Study of CPI-100 in Patients With Advanced Tumors Phase 1
Recruiting NCT03908814 - Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05061628 - The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor Phase 1
Recruiting NCT03444714 - Phase I Study of RiMO-301 With Radiation in Advanced Tumors Phase 1